DIFF Subgroup
A61P 3/12 for electrolyte homeostasis
Introduced: January 2000
Full Title
Full titles differ between systems:
IPC:
Drugs for disorders of the metabolism > for electrolyte homeostasis
CPC:
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) > for electrolyte homeostasis
IPC and CPC are identically structured here. All 1 subcodes exist in both systems.
1 shared codes have differing titles between IPC and CPC.
IPC defines codes here since 2000.
Child Classifications
Navigate with arrow keys, Enter to open
- A61P 3/14 for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04) since 2000 IPC+CPC Available in IPC and CPC
Top Applicants
Top Applicants (IPC)
Class A61,2013–2023, worldwide · Source: EPO PATSTAT
- PHILIPS ELECTRONICS NL 18,523
- NOVARTIS CH 14,253
- COVIDIEN US 13,953
- ROCHE CH 12,005
- CHINESE ACADEMY OF SCIENCES 11,955
- UNIVERSITY OF CALIFORNIA US 11,692
- HARVARD UNIVERSITY US 11,596
- L'OREAL FR 11,593
- P&G (PROCTER & GAMBLE COMPANY) US 11,297
- OLYMPUS CORPORATION JP 9,594
Top Applicants (CPC)
Class A61,2013–2023, worldwide · Source: EPO PATSTAT
- PHILIPS ELECTRONICS NL 20,621
- NOVARTIS CH 15,792
- ROCHE CH 14,303
- COVIDIEN US 13,862
- HARVARD UNIVERSITY US 13,454
- UNIVERSITY OF CALIFORNIA US 12,798
- P&G (PROCTER & GAMBLE COMPANY) US 12,140
- L'OREAL FR 11,800
- OLYMPUS CORPORATION JP 9,894
- BOSTON SCIENTIFIC SCIMED US 9,513